Axomadol

Axomadol (INN, USAN) (code name EN3324) is a synthetic, centrally-acting opioid analgesic of the benzenoid class which was under investigation by Endo Pharmaceuticals in collaboration with Grünenthal for the treatment of chronic, moderate to severe lower back pain and arthrosis.[1][2] Development was halted after phase II clinical trials as it did not meet the pre-determined clinical endpoints.[3]

Axomadol

Clinical data
ATC code	None
Legal status
Legal status	US: Investigational New Drug
Identifiers
IUPAC name (1R,3R,6R)-6-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-1,3-cyclohexanediol
CAS Number	187219-95-0 187219-99-4
PubChem CID	10221318
ChemSpider	8396810
UNII	B77S5W28H9
CompTox Dashboard (EPA)	DTXSID10171992
Chemical and physical data
Formula	C16H25NO3
Molar mass	279.380 g·mol^−1
3D model (JSmol)	Interactive image
SMILES O[C@]2(c1cc(OC)ccc1)C[C@H](O)CC[C@@H]2CN(C)C
InChI InChI=1S/C16H25NO3/c1-17(2)11-13-7-8-14(18)10-16(13,19)12-5-4-6-15(9-12)20-3/h4-6,9,13-14,18-19H,7-8,10-11H2,1-3H3/t13-,14-,16+/m1/s1 Key:LQJLLAOISDVBJM-FMKPAKJESA-N

See also

• Tramadol

References

1. Chadds Ford (2011-06-30). "Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain" (Press release). Endo Pharmaceuticals. Retrieved 2012-05-11.
2. US Abandoned 20100331424, Schiene K, Bloms-Funke P, Bothmer J, Lefeber C, "Use of Axomadol for Treatment of Arthrosis Pain", published 2010-12-30, assigned to Grünenthal GmbH
3. Chadds Ford (2011-08-17). "Endo Pharmaceuticals Announces Termination of Collaboration with Grunenthal for the Development of Axomadol" (Press release). Endo Pharmaceuticals. Retrieved 2012-05-11.